GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alivus Life Sciences Ltd (BOM:543322) » Definitions » Gross-Profit-to-Asset %

Alivus Life Sciences (BOM:543322) Gross-Profit-to-Asset % : 43.03% (As of Mar. 2025)


View and export this data going back to 2021. Start your Free Trial

What is Alivus Life Sciences Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Alivus Life Sciences's annualized Gross Profit for the quarter that ended in Mar. 2025 was ₹14,678 Mil. Alivus Life Sciences's average Total Assets over the quarter that ended in Mar. 2025 was ₹34,115 Mil. Therefore, Alivus Life Sciences's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2025 was 43.03%.


Alivus Life Sciences Gross-Profit-to-Asset % Historical Data

The historical data trend for Alivus Life Sciences's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alivus Life Sciences Gross-Profit-to-Asset % Chart

Alivus Life Sciences Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Gross-Profit-to-Asset %
Get a 7-Day Free Trial 50.81 46.09 39.30 46.15 41.71

Alivus Life Sciences Quarterly Data
Mar20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 41.80 42.22 36.52 46.24 43.03

Competitive Comparison of Alivus Life Sciences's Gross-Profit-to-Asset %

For the Drug Manufacturers - Specialty & Generic subindustry, Alivus Life Sciences's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alivus Life Sciences's Gross-Profit-to-Asset % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alivus Life Sciences's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Alivus Life Sciences's Gross-Profit-to-Asset % falls into.


;
;

Alivus Life Sciences Gross-Profit-to-Asset % Calculation

Alivus Life Sciences's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Mar. 2025 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Mar. 2025 )/( (Total Assets (A: Mar. 2024 )+Total Assets (A: Mar. 2025 ))/ count )
=13060.32/( (28504.12+34114.53)/ 2 )
=13060.32/31309.325
=41.71 %

Alivus Life Sciences's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2025 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Mar. 2025 )/( (Total Assets (Q: Dec. 2024 )+Total Assets (Q: Mar. 2025 ))/ count )
=14677.96/( (0+34114.53)/ 1 )
=14677.96/34114.53
=43.03 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Mar. 2025) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Alivus Life Sciences Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Alivus Life Sciences's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Alivus Life Sciences Business Description

Traded in Other Exchanges
Address
470, Cardinal Gracious Road, 4th Floor, OIA House, Andheri (East), Mumbai, MH, IND, 400 099
Alivus Life Sciences Ltd, formerly Glenmark Life Sciences Ltd develops, manufactures, and supplies high-quality active pharmaceutical ingredients for cardiovascular disease, central nervous system disease, pain management, diabetes, gastrointestinal disorders, anti-infectives, and other therapeutic areas.

Alivus Life Sciences Headlines

No Headlines